Q2i is a digital health company dedicated to developing, refining, validating, and commercializing innovative, evidence-based solutions.

Q2i’s Business Divisions

science and research based

Science, Research, and Evidence Base

In conjunction with the National Institutes of Health, and collaboration with various academic partners Q2i designs, develops, refines, tests, and empirically measures its technology’s efficacy in impacting and improving target outcomes.

CMI Logo<br />

Contingency Management

More organizations rely on Q2i’s CMI Technology to address and overcome the burdens, barriers, and challenges of implementing and managing CM and improve CM programs’ accuracy, immediacy, fidelity, security, and success than all our competitors combined.

criminal justice managment

Criminal Justice Solutions

Q2i’s patented “PARCA” technology developed through funding and oversight by the National Institutes of Health works to help improve the success of probation and parole/community supervision, reducing recidivism, rearrests, and reincarcerations.

News:

Q2i’s PARCA Technology Moves to Phase II of National Institutes of Health (NIH) Clinical Trial to Further Evaluate Its Efficacy in Increasing Community Supervision Success

22 Jan, 2025  |  Read more ›

Q2i Secures Patent for PARCA Solution, Revolutionizing Probation and Parole.

7 Jan, 2025  |  Read more ›

News Archive:

Q2i’s reward-based digital technology moves to Phase II of National Institutes of Health (NIH) clinical trial to further evaluate the application’s efficacy in increasing treatment adherence for substance use disorder after an ED Visit.

Read more ›


Q2i’s OARS software application moves to Phase II of National Institute of Health (NIH) clinical trial which will evaluate the application’s efficacy in improving Opioid Use Disorder treatment

Read more ›


Q2i Awarded NIH/NIDA Grant to Develop and Evaluate Digital Technology to Improve Successful Community Reintegration of Recently Released Justice-Involved Individuals With Substance Use Disorders

Read more ›


Q2i Awarded NIH/NIDA Grant to Develop and Evaluate Digital Technology to Improve Medication-Assisted Treatment in Primary Care

Read more ›


Q2i Awarded NIH/NIDA Grant to Develop and Evaluate Loyalty/Reward-based Digital Technology to Increase Medication Adherence for Substance Use Disorder after an ED Visit


Beacon Health Options announce they have selected Q2i’s OARS technology in a grant award to address the opioid crisis.


The Haven Substance Abuse Recovery Center Adopts Q2i’s CASA Technology to Increase Efficacy of After-Treatment Care


Q2i Adds Telehealth Capabilities to Its Solutions, Improving Availability and Access to Recovery from Opioid Addiction


Q2i’s Outcome-Measures Software Helping Improve Quality of Treatment for Substance Use Disorder


Q2i’s New MATRA Technology Enables Earliest Interventions to Improve Recovery from Opioid Use Disorder


Q2i’s technology proving successful in supporting fight against opioid epidemic


Harbor Homes becomes first healthcare organization in New Hampshire to utilize OARS technology to improve treatment for opioid use disorder


Maine-Based Door to Door Doctors Deploys Q2i’s OARS Technology to Support Patients Recovering from Opioid Use Disorder


The PILLARS Recovery Center Deploys Q2i’s CASA Technology To Better Support People In Recovery from Substance Abuse


Alyssa’s Place: Peer Recovery Center Deploys Q2i’s CASA Technology to Improve After-Treatment Care of Substance Use Disorder Patients


Q2i Partners with athenahealth’s ‘More Disruption Please’ Program to Enable Providers to Gain Insight into OUD Patients’ Recovery Progress and Improve Patient Outcomes


Q2i launches CASA, technology supporting residential and outpatient recovery clinics with their after treatment programs


Technology proving successful in supporting fight against opioid epidemic


Using Technology to Battle the Opioid Epidemic – Health Tech Company, Q2i, Launches its Innovative behavioral healthcare management software, OARS

Reviews